T1	p 85 116	invasive diarrhea in children .
T2	p 190 198	children
T3	p 369 392	acute invasive diarrhea
T4	p 425 440	southern Israel
T5	p 714 761	diarrhea in infants and children . PATIENTS AND
T6	p 770 964	From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room
T7	p 1218 1231	Campylobacter
T8	p 1462 1470	patients
T9	p 2423 2488	ambulatory pediatric patients requiring an emergency room visit .
T10	i 6 65	Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric
T11	i 281 320	antibiotics , intramuscular ceftriaxone
T12	i 665 678	ciprofloxacin
T13	i 999 1028	ciprofloxacin suspension ( 10
T14	i 1043 1063	day + im placebo ; n
T15	i 1069 1124	) or im ceftriaxone ( 50 mg/kg/day + placebo suspension
T16	i 1803 1816	ciprofloxacin
T17	i 1821 1832	ceftriaxone
T18	i 2110 2123	ciprofloxacin
T19	i 2138 2149	ceftriaxone
T20	i 2293 2311	Oral ciprofloxacin
T21	i 2355 2366	ceftriaxone
T22	o 79 102	acute invasive diarrhea
T23	o 134 151	invasive diarrhea
T24	o 227 258	resistance of enteric pathogens
T25	o 384 392	diarrhea
T26	o 576 584	diarrhea
T27	o 614 633	efficacy and safety
T28	o 699 722	acute invasive diarrhea
T29	o 924 932	diarrhea
T30	o 1325 1353	Clinical response and safety
T31	o 1430 1443	127 pathogens
T32	o 1575 1611	Overall bacteriologic eradication on
T33	o 1738 1766	Clinical cure or improvement
T34	o 1857 1883	Serum ciprofloxacin values
T35	o 2056 2083	drug-related adverse events
T36	o 2184 2213	transient . Joint examination
T37	o 2396 2433	acute invasive diarrhea in ambulatory